Cases & Deals

  • Home
  • Practices
  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent Office

Share

Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent Office

August 2019

Client(s) Regeneron Pharmaceuticals, Inc.; Sanofi

Jones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.